Want to see CING full AI Analyst Report?
CING Stock Chart & Stats
$5.45
-$0.31(-6.60%)
At close: 4:00 PM EST
$5.45
-$0.31(-6.60%)
Day’s Range― - ―
52-Week Range$3.16 - $11.89
Previous CloseN/A
Volume136.88K
Average Volume (3M)190.99K
Market Cap
$66.13M
Enterprise Value$10.24M
Total Cash (Recent Filing)$25.89M
Total Debt (Recent Filing)$7.43M
Price to Earnings (P/E)―
Beta5.09
Next Earnings
Aug 18, 2026EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.02
Shares Outstanding13,469,036
10 Day Avg. Volume270,731
30 Day Avg. Volume190,985
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.40
Price to Sales (P/S)0.00
P/FCF Ratio-1.35
Enterprise Value/Market Cap0.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.43
Forecast
1Y Price Target
$22.50Price Target Upside312.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.37
Revenue Forecast (FY)$3.63M
Bulls Say, Bears Say
Bulls Say
Strengthened IP ProtectionA composition/formulation patent through 2042 secures exclusive rights to the PTR once-daily architecture, supporting long-term commercialization, deterrence of generic entrants, and stronger licensing or partnership leverage as the company advances CTx-1301 and platform applications.
Index Inclusion Enhances VisibilityRussell 3000E inclusion broadens institutional visibility and passive investor access, which can materially improve capital market access and liquidity over months, lowering fundraising friction for a development-stage biotech pursuing additional financing or partner deals.
Near-term Cash To Fund CMC WorkHaving roughly $30M earmarked to complete CMC activities and resubmit the NDA materially reduces immediate financing pressure, enabling continued development and pre-commercial planning into 2027 and improving the odds of progressing to approval without immediate dilution.
Bears Say
Persistent No Revenue And LossesMulti-year absence of product revenue and recurring operating losses (annual net losses historically ~$15M–$24M) mean the company is fully financing development via capital markets, increasing dilution risk and reducing financial resilience until commercial sales or partner income materialize.
High Leverage And Balance Sheet InstabilityA leveraged capital structure and past negative equity indicate funding vulnerability: elevated refinancing risk, higher financing costs, and weaker negotiating stance with partners. This structural constraint can force costly capital raises or unfavorable deal terms as development expenses persist.
Regulatory Setback: FDA CRLA CRL on CMC issues postpones potential approval and commercialization, raising timeline and cost uncertainty. CMC deficiencies often require manufacturing adjustments and additional documentation or inspections, increasing execution risk and potentially extending capital needs before revenue realization.
Cingulate Inc News
CING FAQ
What was Cingulate Inc’s price range in the past 12 months?
Cingulate Inc lowest stock price was $3.16 and its highest was $11.89 in the past 12 months.
What is Cingulate Inc’s market cap?
Cingulate Inc’s market cap is $66.13M.
When is Cingulate Inc’s upcoming earnings report date?
Cingulate Inc’s upcoming earnings report date is Aug 18, 2026 which is in 34 days.
How were Cingulate Inc’s earnings last quarter?
Cingulate Inc released its earnings results on May 14, 2026. The company reported -$0.95 earnings per share for the quarter, missing the consensus estimate of -$0.52 by -$0.43.
Is Cingulate Inc overvalued?
According to Wall Street analysts Cingulate Inc’s price is currently Undervalued.
Does Cingulate Inc pay dividends?
Cingulate Inc does not currently pay dividends.
What is Cingulate Inc’s EPS estimate?
Cingulate Inc’s EPS estimate is -0.63.
How many shares outstanding does Cingulate Inc have?
Cingulate Inc has 13,469,036 shares outstanding.
What happened to Cingulate Inc’s price movement after its last earnings report?
Cingulate Inc reported an EPS of -$0.95 in its last earnings report, missing expectations of -$0.52. Following the earnings report the stock price went down -10.772%.
Which hedge fund is a major shareholder of Cingulate Inc?
Currently, no hedge funds are holding shares in CING
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cingulate Inc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.50 (312.84% Upside)
$22.50 (312.84% Upside)
Hedge Fund Trend
Decreased
By 97.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $490.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.59%
12-Months-Change
Fundamentals
Return on Equity
-365.16%
Trailing 12-Months
Asset Growth
147.50%
Trailing 12-Months
Company Description
Cingulate Inc
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.
CING Stock 12 Month Forecast
Average Price Target
$22.50
▲(312.84% Upside)
Technical Analysis
Bio Green Med Solution
―
NanoViricides
―
Enlivex
―
FibroBiologics, Inc.
―
Boundless Bio Inc.
―
Ownership Overview
1.93% Insiders
2.80% Mutual Funds
1.00% Other Institutional Investors
91.15% Public Companies and
Individual Investors